Literature DB >> 7977633

CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury.

W W Hancock1, D H Adams, L R Wyner, M H Sayegh, M J Karnovsky.   

Abstract

Studies of T cell-deficient or immunosuppressed animals undergoing arterial endothelial denudation have yielded conflicting results as to the contribution of the immune system to neointimal vascular smooth muscle cell accumulation and proliferation. We investigated the cell types and cytokine expression associated with intimal hyperplasia occurring 14 days after balloon angioplasty of the carotid artery in Sprague-Dawley rats. Immunohistological studies using monoclonal antibodies showed that the carotid luminal occlusion observed was associated with smooth muscle cell proliferation and neointimal accumulation of large numbers of CD4+, ED1+ mononuclear cells but no T cells. There was also wide-spread staining for the inflammatory cytokine interleukin-1B (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), and IL-8, as well as dense expression of the potent smooth muscle mitogens platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), and protein S. The relationship of smooth muscle cell proliferation to monocyte/macrophage accumulation and cytokine expression was tested by daily intraperitoneal administration for 14 days of a rat CD4-specific monoclonal antibody, BWH-4 (500 micrograms/day). Morphometric analysis at day 14 showed that the intimal area of animals treated with CD4 monoclonal antibody comprised 7% +/- 4% of the arterial wall compared with 50% +/- 6% in control animals (n = 6/group, P < 0.001). In addition, immunohistological studies showed that CD4 monoclonal antibody treatment markedly reduced the intimal accumulation of mononuclear and smooth muscle cells and essentially abrogated expression of the cytokines PDGF-BB, TGF-beta, IL-1 beta, TNF-alpha, and IL-8, plus the anticoagulant molecule, protein S. Our results document the extensive expression in vivo of cytokines that in vitro promote vascular smooth muscle cell proliferation, and suggest that CD4+ mononuclear cells or their secreted products play a key role in the pathogenesis of intimal hyperplasia after endothelial injury. Furthermore, these observations may have clinical relevance in the development of novel strategies to prevent arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7977633      PMCID: PMC1887438     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells.

Authors:  G P Gasic; C P Arenas; T B Gasic; G J Gasic
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.

Authors:  G A Ferns; E W Raines; K H Sprugel; A S Motani; M A Reidy; R Ross
Journal:  Science       Date:  1991-09-06       Impact factor: 47.728

Review 3.  Smooth muscle cell growth factors.

Authors:  W Casscells
Journal:  Prog Growth Factor Res       Date:  1991

Review 4.  CD4 monoclonal antibodies in organ transplantation--a review of progress.

Authors:  T Sablinski; W W Hancock; N L Tilney; J W Kupiec-Weglinski
Journal:  Transplantation       Date:  1991-10       Impact factor: 4.939

5.  Experimental graft arteriosclerosis. I. The Lewis-to-F-344 allograft model.

Authors:  D H Adams; N L Tilney; J J Collins; M J Karnovsky
Journal:  Transplantation       Date:  1992-05       Impact factor: 4.939

6.  Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy.

Authors:  W W Hancock; M H Sayegh; T Sablinski; J P Kut; J W Kupiec-Weglinski; E L Milford
Journal:  Transplantation       Date:  1992-06       Impact factor: 4.939

7.  Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absence of functional T lymphocytes.

Authors:  G A Ferns; M A Reidy; R Ross
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

8.  Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response.

Authors:  W W Hancock; S J Khoury; C B Carpenter; M H Sayegh
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

9.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury.

Authors:  E R Edelman; D H Adams; M J Karnovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 10.  Pathology of cardiac transplantation: recipient hearts (chronic heart failure) and donor hearts (acute and chronic rejection).

Authors:  H D Tazelaar; W D Edwards
Journal:  Mayo Clin Proc       Date:  1992-07       Impact factor: 7.616

View more
  21 in total

Review 1.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

2.  Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge.

Authors:  H Epstein; E Grad; M Golomb; N Koroukhov; E R Edelman; G Golomb; H D Danenberg
Journal:  Atherosclerosis       Date:  2007-12-11       Impact factor: 5.162

3.  CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis.

Authors:  K S Kim; M D Denton; A Chandraker; A Knoflach; R Milord; A M Waaga; L A Turka; M E Russell; R Peach; M H Sayegh
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  Increased Oxidative Stress and Hypoxia Inducible Factor-1 Expression during Arteriovenous Fistula Maturation.

Authors:  Nirvana Sadaghianloo; Kota Yamamoto; Hualong Bai; Masayuki Tsuneki; Clinton D Protack; Michael R Hall; Serge Declemy; Réda Hassen-Khodja; Joseph Madri; Alan Dardik
Journal:  Ann Vasc Surg       Date:  2017-02-03       Impact factor: 1.466

5.  Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice.

Authors:  X Zhou; S Stemme; G K Hansson
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

6.  Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice.

Authors:  E E Emeson; M L Shen; C G Bell; A Qureshi
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

7.  Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.

Authors:  Jason C Gardenier; Geoffrey E Hespe; Raghu P Kataru; Ira L Savetsky; Jeremy S Torrisi; Gabriela D García Nores; Joseph J Dayan; David Chang; Jamie Zampell; Inés Martínez-Corral; Sagrario Ortega; Babak J Mehrara
Journal:  JCI Insight       Date:  2016-09-22

8.  Relationship between HLA molecules and late restenosis after coronary stent placement.

Authors:  Hasan Kudat; Mustafa Ozcan; Tufan Tükek; Ahmet Bilge Sözen; Vakur Akkaya; Fatma Oguz; Yalçın Seyhun
Journal:  J Saudi Heart Assoc       Date:  2011-10-18

9.  Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat.

Authors:  Yuko Hara; Yoshiaki Kusumi; Masako Mitsumata; Xiao-Kang Li; Masayuki Fujino
Journal:  J Thromb Thrombolysis       Date:  2007-10-26       Impact factor: 2.300

10.  Urinary trypsin inhibitor reduced neointimal hyperplasia induced by systemic inflammation after balloon injury in rabbits.

Authors:  Junying Kong; Jian Zhang; Lin Li; Guihua Jiang; Xinchun Wang; Xiaojun Liu; Bo Yu
Journal:  Inflamm Res       Date:  2012-10-27       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.